Evidence mapPaperPMID 42426281Full record

ArticleDiscover nano2026

Oridonin loaded amphiphilic hyaluronic acid polymeric micelle with tunable redox sensitive property for CD44 targeted lung cancer therapy.

Shaoyan Xuan, Shenglei Yang, Yuqin Mao, Zhiyong Chen, Yue Zhu, Ying Zhou, Jie Huang, Xiuliang Zhu, Zuhua Wang

Abstract read
In one paragraph

Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shaoyan XuanDepartment of Pharmacy, Shaoxing People's Hospital, Zhongxing North road 568, Shaoxing, 312000, China.
Shenglei YangCollege of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Yuqin MaoDepartment of Pharmacy, Shaoxing People's Hospital, Zhongxing North road 568, Shaoxing, 312000, China.
Zhiyong ChenCollege of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Yue ZhuCollege of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Ying ZhouCollege of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Jie HuangShaoxing Seventh People's Hospital (Affiliated Mental Health Center, Medical College of Shaoxing University), Shengli West Road 1234, Shaoxing, 312000, China. sxskqyy_hj@163.com.
Xiuliang ZhuDepartment of radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, Zhejiang, PR China. zhuxiul@zju.edu.cn.
Zuhua WangCollege of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China. wangrui551601@163.com.ORCID https://orcid.org/0000-0001-7076-1014

Funding

Basic Public Welfare Research Project of Zhejing Province LY22H180004Guangzhou Pukang Charity Foundation project 2023XH01Guizhou Key Laboratory of Modern Traditional Chinese Medicine Creation Qian Ke He Platform ZSYS [2025] 019High-level Innovative Talents of Guizhou Province High-level Innovative Talents of Guizhou ProvinceMedical Health Science and Technology Project of Zhejiang Provincial Health Commission 2022KY1302Nano-drug Technology Research Center of Guizhou University of Traditional Chinese Medicine Guizhongyi ZX Hezi [2024]070National Administration of Traditional Chinese Medicine High-level Key Disciplines Development Project zyyzdxk-2023185Science and Technology Program of Guizhou Province Qiankehe Basics ZK [2023] Key 046the National Natural Science Foundation of China 82360852, 81760643Traditional Chinese Medicine Preparation and Big Health Products Development-Guizhou Provincial Science and Technology Innovation Leading Talent Workstation Qiankehe Platform KXJZ [2025] No. 042
6 · The paper itself

Abstract

Lung cancer remains one of the most prevalent and lethal malignancies worldwide. Oridonin (ORI) exhibits remarkable anti-lung cancer activity. Nevertheless, its clinical application in lung cancer therapy is severely hindered by poor solubility, fast metabolism, insufficient tumor penetration, and low selectivity. In this study, we developed a redox-responsive polymeric micelle (HA-cys-TOS) targeting the CD44 receptor to improve ORI bioavailability and tumor targeting. The polymer was synthesized via esterification and verified by

Indexed as

CD44 receptorHyaluronic acidLung cancerOridoninRedox-sensitive

Identifiers

PMID42426281
PMCPMC13350622

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.